News & Publications

5 April 2017

EBODAC CONSORTIUM ORGANIZES SYMPOSIUM ON COMMUNITY ENGAGEMENT, COMMUNICATIONS AND TECHNOLOGY IN EBOLA CLINICAL TRIALS IN SENEGAL

Eighteen months on from the epidemic that cost the lives of more than 11,000 people in West Africa, the EBODAC consortium hosted a symposium in Dakar (Senegal) to enable exchange of lessons learned in using community engagement, communication and technology while conducting clinical trials related to Ebola in an outbreak setting.

Read the full story.


 

14 March 2017

INVESTIGATIONAL EBOLA VACCINE REGIMEN INDUCED DURABLE IMMUNE RESPONSE 1 YEAR AFTER VACCINATION IN PHASE 1 STUDY

Johnson & Johnson announced that final Phase 1 clinical trial data published in JAMA: The Journal of the American Medical Association show that Janssen Pharmaceutical Companies’ investigational “prime-boost” Ebola vaccine regimen induced a durable immune response in 100 percent of healthy volunteers one year following vaccination.

Read the full story.


 

13 March 2017

EBOVAC1 AND EBODAC IMI PERIODIC REPORTS SUBMITTED

 


 

19 April 2016

GLOBAL PUBLIC-PRIVATE PARTNERSHIP ANNOUNCES PUBLICATION OF POSITIVE PHASE 1 DATA FOR EBOLA VACCINE REGIMEN IN JAMA 

A public-private partnership of some of the world’s leading health organizations today announced that data from a Phase 1 study of a preventive Ebola vaccine regimen have been published in JAMA: The Journal of the American Medical Association. The results, the first published on the vaccine regimen, suggest that the regimen was well-tolerated by healthy volunteers and immunogenic (produced an immune response). Among the findings, 100 percent of participants in the study achieved an initial antibody response to Ebola, and this response was sustained 8 months following immunization. The study was led by the Oxford Vaccine Group at the University of Oxford Department of Paediatrics and took place in the United Kingdom.

Read the full story.


 

9 October 2015

CLINICAL TRIAL FOR NEW EBOLA VACCINE STARTS IN KAMBIA DISTRICT, SIERRA LEONE

‘EBOVAC-Salone’, a clinical trial to assess the safety and immunogenicity of a new vaccine against Ebola, has started with the vaccination of the first volunteers. The first volunteers to be vaccinated come from Kambia Town, and more volunteers from Kambia District will be enrolled in the study in stages over the course of the next few months.

Read the full story.

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
www.imi.europa.eu
Copyright © 2017 Ebovac | Terms and Conditions | WordPress development by Toast.